Susan Griffin

Search results

• 2020

  Does Health Technology Assessment guidance give adequate consideration to decisions about less costly and less effective alternatives?

  Griffin, S., Fusco, F., Naidoo, B., Taylor, M. & Walker, S. M., 4 Nov 2020, York, UK: Centre for Health Economics, University of York, 19 p. (CHE Research Paper; no. 175).

  Research output: Working paper

  Open Access

  File
• 2011

  Uncertainty, evidence and irrecoverable costs: informing approval, pricing and research decisions for health technologies

  Claxton, K. P., Palmer, S. J., Longworth, L., Bojke, L., Griffin, S., McKenna, C., Soares, M. O., Spackman, E. & Youn, J., Oct 2011, York, UK: Centre for Health Economics, University of York, 81 p. (CHE Research Paper; no. 69).

  Research output: Working paper

  Open Access

  File
• 2009

  Cetuximab plus radiotherapy for the treatment of locally advance squamous cell carcinmoa of the head and neck

  Griffin, S., Walker, S. & Sculpher, M., 2009.

  Research output: Working paper

• The use of paclitaxel in the management of early stage breast cancer.

  Griffin, S., Dunn, G., Palmer, S., Macfarlane, S., Brent, S., Dyker, A., Erhorn, A., Humphries, C., White, S., Horsley, W., Ferrie, L. & Thomas, S., 2009.

  Research output: Working paper

• 2006

  Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer (update): a systematic review and economic evaulation

  Main, C., Ginnelly, L., Griffin, S., Norman, G., Barbieri, M., Mather, L., Stark, D., Palmer, S. & Riemsma, R., 2006.

  Research output: Working paper